Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study

Abstract Background The integration of transarterial chemoembolization (TACE) with systemic therapy has demonstrated improved survival outcomes in patients with unresectable hepatocellular carcinoma (HCC). However, there is limited evidence evaluating the combination of TACE with the systemic regime...

Full description

Saved in:
Bibliographic Details
Main Authors: Lingzhan Meng, Hu Li, Yingjie Ji, Peng Yu, Zizheng Wang, Li Cao, Bin Shi, Yanling Shao, Jin Yan, Yinjie Gao, Zhenyu Zhu
Format: Article
Language:English
Published: Springer 2024-11-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Combination therapy
Hepatocellular carcinoma
Lenvatinib
Sintilimab
Transarterial chemoembolization (TACE)
Online Access:https://doi.org/10.1007/s00262-024-03857-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items